News Another 340B lawsuit gets underway, in Illinois Three pharma groups have opened a new front in their legal challenge to the federal 340B drug pricing programme in the US.
News Manufacturing issues mar ITM's radiopharma filing, says FDA ITM's first attempt to score FDA approval for one of its radiopharma therapies has been knocked back by the agency.
News UK is first European country to approve Lilly's Foundayo Eli Lilly's oral GLP-1 agonist Foundayo has been approved for weight management and type 2 diabetes in the UK, its first European market.
News TransThera's resistant biliary cancer drug cleared in China TransThera's Yochanra has been cleared in China as the world's first drug that can overcome resistance to FGFR inhibitors in cholangiocarcinoma.
News Third time lucky for Replimune as FDA OKs melanoma drug At its third attempt, Replimune has finally won FDA approval for its advanced melanoma treatment RP1, now named Tudriqev and its first product.
News Novo Nordisk wins Netherlands GLP-1 compounding lawsuit A Dutch compounding pharmacy has been ordered to stop distributing a compounded nasal spray version of Novo Nordisk's GLP-1 agonist semaglutide.
News ESMO26: Lily's sofe-m ADC stakes a claim in ovarian cancer Eli Lilly's first major readout at ESMO comes from a phase 1 trial of its FRα-targeting sofe-m in platinum-sensitive ovarian cancer (PSOC).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
